Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of Cytotoxic Properties of N,N'-bis[(1-aryl-3-heteroaryl)propylidene]-hydrazine dihydrochlorides

  • Published:
Pharmaceutical Chemistry Journal Aims and scope

N,N'-bis[(1-aryl-3-heteroaryl)propylidene]hydrazine dihydrochlorides, P1, P4 – P8, and R1 – R7, were assayed against human oral squamous cell carcinoma (HSC-2, HSC-3, HSC-4), human promyelocytic leukemia cell line (HL-60), and human normal oral cells (HGF, HPC, and HPLF) as non-tumor cells to evaluate their cytotoxic properties. Peplomycin was used as a reference compound. It was found that P- and R-series hydrazone compounds exhibited cytotoxicity in a range of 11 ± 0.68 – 300 ± 1.0 ± M. Compound P1 which is a non-substituted hydrazone containing piperidine ring and compound R2 which is a 4-methyl hydrazone derivative containing pyrrolidine ring showed the most potent cytotoxic activity. These hydrazone compounds may serve as promising candidates for further studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Scheme 1.

Similar content being viewed by others

References

  1. G. Stork and J. Benaim, J. Org. Synth., 6, 242 (1977).

    Google Scholar 

  2. A. C. Day and M. C. Whiting, J. Org. Synth., 6, 10 (1970).

    Google Scholar 

  3. E. Corey and D. Enders, Tetrahedron Lett., 17(1), 3 – 6 (1976).

    Google Scholar 

  4. E. Corey and D. Enders, Tetrahedron Lett., 17(1), 11 – 14 (1976).

    Google Scholar 

  5. S. Schöfer, J. Prak. Chem., 51, 185 (1850).

    Google Scholar 

  6. N. P. Belskaya, W. Dehaen, and V. A. Bakulev, ARKIVOC, Part (i), 275 – 332 (2010).

  7. M. Asif and A. Husain, J. Appl. Chem., 2013, 1 – 7 (2013).

    Google Scholar 

  8. P. Vicini, M. Incerti, I. A. Doytchinova, et al., Eur. J. Med. Chem., 41(5), 624 – 632 (2006).

    CAS  PubMed  Google Scholar 

  9. J. Mao, Y. Wang, B. Wan, et al., Chem. Med. Chem., 2(11), 1624 – 1630 (2007).

    CAS  PubMed  Google Scholar 

  10. R. Narisetty, K. B. Chandrasekhar, S. Mohanty, et al., LDDD, 10(7), 620 – 624 (2013).

    CAS  Google Scholar 

  11. B. Evranos-Aksöz, S. Yabanoðlu-Çiftçi, G. Uçar, et al., Bioorg. Med. Chem. Lett., 24(15), 3278 – 3284 (2014).

    PubMed  Google Scholar 

  12. V. Mashayekhi, K. H. M. E. Tehrani, S. Amidi, et al., Chem. Pharm. Bull., 61(2), 144 – 150 (2013).

    CAS  Google Scholar 

  13. Z. A. Kaplancýklý, L. Yurttaþ, A. Özdemir, et al., Med. Chem. Res., 23(2), 1067 – 1075 (2014).

    Google Scholar 

  14. E. B. Lindgren, M. A. de Brito, T. R. Vasconcelos, et al., Eur. J. Med. Chem., 86, 12 – 16 (2014).

    CAS  PubMed  Google Scholar 

  15. K. Kucukoglu, M. Gul, M. Atalay, et al., Arzneimittelforschung, 61(6), 366 – 371 (2011).

    CAS  PubMed  Google Scholar 

  16. K. Kucukoglu, H. I. Gul, R. Cetin-Atalay, et al., J. Enzyme Inhib. Med. Chem., 29(3), 420 – 426 (2014).

    CAS  PubMed  Google Scholar 

  17. K. Kucukoglu, H. I. Gul, M. Gul, et al., LDDD, 13(8), 734 – 741 (2016).

    CAS  Google Scholar 

  18. K. Kucukoglu, M. Gul, H. I. Gul, et al., Med. Chem. Res., 27, 2116 – 2124 (2018).

    CAS  Google Scholar 

  19. M. Tramontini, Synthesis, 1973(12), 703 – 775 (1973).

    Google Scholar 

  20. M. Tramontini and L. Angiolini, Tetrahedron, 46(6), 1791 – 1837 (1990).

    CAS  Google Scholar 

  21. L. Racane, V. Traliæ-Kulenoviæ, Lelja Fiser-Jakic, et al., Heterocycles, 55(11), 2085 – 2098 (2001).

    CAS  Google Scholar 

  22. E. Kashiyama, I Hutchinson, and M. S. Chua, J. Med. Chem., 42(20), 4172 – 4184 (1999).

    CAS  PubMed  Google Scholar 

  23. S. R. Bhusare, R. Pawar, and Y. B. Vibhute, Indian J. Het. Chem., 11(1), 79 – 80 (2001).

    CAS  Google Scholar 

  24. E. Mete, C. Ozelgul, C. Kazaz, et al., Arch. Pharm. (Weinheim), 343(5), 291 – 300 (2010).

    CAS  Google Scholar 

  25. E. Mete, H. I. Gul, S. Bilginer, et al., Molecules, 16(6), 4660 – 4671 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  26. B. N. Singh, S. K. Shukla, and M. Singh, Asian J. Chem., 19(7), 5013 – 5018 (2007).

    CAS  Google Scholar 

  27. H. I. Gul, F. Sahin, M. Gul, et al., Arch. Pharm. (Weinheim), 338(7), 335 – 338 (2005).

    CAS  Google Scholar 

  28. M. Gul, M. Atalay, H. I. Gul, et al., Toxicol. In Vitro, 19(5), 573 – 580 (2005).

    CAS  PubMed  Google Scholar 

  29. M. Ashok, B. S. Holla, and B. Poojary, Eur. J. Med. Chem., 42(8), 1095 – 1101 (2007).

    CAS  PubMed  Google Scholar 

  30. H. I. Gul, H. Suleyman, and M. Gul, Pharmaceutical Biology, 47(10), 968 – 972 (2009).

    CAS  Google Scholar 

  31. Y. N. Şahin, B. Demircan, H. Süleyman, et al., Turk. J. Med. Sci., 40(5), 723 – 728 (2010).

    Google Scholar 

  32. M. Köksal, N. Gökhan, and E. Küpeli, et al., Arch. Pharm. Res., 30(4), 419 – 424 (2007).

    PubMed  Google Scholar 

  33. D. Sriram, D. Banerjee, and P. Yogeeswari, J. Enzyme Inhib. Med. Chem., 24(1), 1 – 5 (2009).

    CAS  PubMed  Google Scholar 

  34. M. Tugrak, H. I. Gul, K. Bandow, et al., Bioorg. Chem., 90, 103095 (2019).

    CAS  PubMed  Google Scholar 

  35. H. I. Gul, M. Tugrak, M. Gul, et al., Bioorg. Chem., 90, 103057 (2019).

    CAS  PubMed  Google Scholar 

  36. H. I. Gul, A. Demirtas, G. Ucar, et al., LDDD, 14(5), 573 – 580 (2017).

  37. C. Yamali, H. I. Gul, H. Sakagami, et al., J. Enzyme Inhib. Med. Chem., 31(sup4), 125 – 131 (2016).

  38. H. I. Gul, Z. Yazici, M. Tanc, et al., J. Enzyme Inhib. Med. Chem., 31(6), 1540 – 1544 (2016).

    CAS  PubMed  Google Scholar 

  39. D. O. Ozgun, C. Yamali, H. I. Gul, et al., J. Enzyme Inhib. Med. Chem., 31(6), 1498 – 1501 (2016).

    CAS  PubMed  Google Scholar 

  40. H. I. Gul, C. Yamali, A. T. Yasa, et al., J. Enzyme Inhib. Med. Chem., 31(6), 1375 – 1380 (2016).

    Google Scholar 

  41. S. Bilginer, H. I. Gul, E. Mete, et al., J. Enzyme Inhib. Med. Chem., 28(5), 974 – 980 (2013).

    CAS  PubMed  Google Scholar 

  42. M. Tugrak, C. Yamali, H. Sakagami, et al., J. Enzyme Inhib. Med. Chem., 31(5), 818 – 823 (2016).

    CAS  PubMed  Google Scholar 

  43. M. Tugrak, H. I. Gul, H. Sakagami, et al., LDDD, 12(10), 806 – 812 (2015).

    CAS  Google Scholar 

  44. K. O. Yerdelen, H. I. Gul, H. Sakagami, et al., J. Enzyme Inhib. Med. Chem., 30(3), 383 – 388 (2015).

    CAS  PubMed  Google Scholar 

  45. K. O. Yerdelen, H. I. Gul, H. Sakagami, et al., LDDD, 12(8), 643 – 649 (2015).

  46. H. I. Gul, M. Tugrak, and H. Sakagami, J. Enzyme Inhib. Med. Chem., 31(1), 147 – 151 (2016).

    CAS  PubMed  Google Scholar 

  47. E. Unluer, H. I. Gul, A. Demirtas, et al., J. Enzyme Inhib. Med. Chem., 31(sup3), 105 – 109 (2016).

  48. K. Kucukoglu, E. Mete, R. Cetin-Atalay, et al., J. Enzyme Inhib. Med. Chem., 30(4), 564 – 568 (2015).

    CAS  PubMed  Google Scholar 

  49. C. Yamali, D. O. Ozgun, H. I. Gul, et al., Med. Chem. Res., 26(9), 2015 – 2023 (2017).

    CAS  Google Scholar 

  50. M. Tugrak, H. I. Gul, H. Sakagami, et al., Med. Chem. Res., 26(7), 1528 – 1534 (2017).

    CAS  Google Scholar 

  51. N. Motohashi, H. Wakabayashi, T. Kurihara, et al., Phytother. Res. 18(3), 212 – 223 (2004).

    PubMed  Google Scholar 

  52. D. O. Ozgun, H. I. Gul, C. Yamali, et al., Bioorg. Chem., 84, 511 – 517 (2019).

    Google Scholar 

  53. M. Tugrak, H. I. Gul, H. Sakagami, et al., Bioorg. Chem., 81, 433 – 439 (2019).

    Google Scholar 

  54. H. I. Gul, C. Yamali, G. Gunesacar, et al., Med. Chem. Res., 27(10), 2366 – 2378 (2018).

    CAS  Google Scholar 

  55. H. I. Gul, C. Yamali, H. Sakagami, et al., Bioorg. Chem., 77, 411 – 419 (2018).

    CAS  PubMed  Google Scholar 

  56. H. I. Gul, M. Tugrak, M. Gul, et al., Anticancer Agents Med. Chem., 18(12), 1770 – 1778 (2018).

    CAS  PubMed  Google Scholar 

  57. C. Yamali, H. I. Gul, D. O. Ozgun, et al., Anticancer Agents Med. Chem., 17(10), 1426 – 1433 (2017).

    CAS  PubMed  Google Scholar 

  58. H. I. Gul, E. Mete, S. E. Eren, et al., J. Enzyme Inhib. Med. Chem., 32(1), 169 – 175 (2017).

    CAS  PubMed  Google Scholar 

  59. K. Kucukoglu, F. Oral, T. Aydin, et al., J. Enzyme Inhib. Med. Chem., 31(S4), 20 – 24 (2016).

  60. H. I. Gul, M. Tugrak, H. Sakagami, et al., J. Enzyme Inhib. Med. Chem., 31(6), 1619 – 1624 (2016).

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by the Research Foundation of Ataturk University Erzurum (Turkey).

Conflict of Interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Selcuk University, Konya, Turkey

    K. Kucukoglu

  2. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ataturk University, Erzurum, Turkey

    H. I. Gul

  3. Meikai University Research Institute of Odontology (M-RIO), Saitama, Sakado, 350-0283, Japan

    H. Sakagami

Authors
  1. K. Kucukoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. I. Gul
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Sakagami
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Kucukoglu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kucukoglu, K., Gul, H.I. & Sakagami, H. Evaluation of Cytotoxic Properties of N,N'-bis[(1-aryl-3-heteroaryl)propylidene]-hydrazine dihydrochlorides. Pharm Chem J 54, 784–787 (2020). https://doi.org/10.1007/s11094-020-02274-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11094-020-02274-z

Keywords

Search

Navigation